AstraZeneca is a global, science-led, patient-focused biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines for some of the world’s most serious diseases. But we’re more than one of the world’s leading pharmaceutical companies. We are on a journey to bring life-saving medicines to patients. Our role in contributing to decreasing mortality rates globally is clear – shaping the future by spotting a scientifically-led commercial opportunity and acting now to operationalize and scale it.
At AstraZeneca, we put patients first and strive to meet their unmet needs worldwide. Working here means being entrepreneurial, thinking big and working together to make the impossible a reality. If you are swift to action, confident to lead, willing to collaborate, and curious about what science can do, then you’re our kind of person.
As a Foreign Invested Enterprise with over 600 members, AstraZeneca is investing into Vietnam 360 million USD from 2020 to 2030 with a focus on reducing the burdens of non-communicable diseases, developing local talent, and uplifting the domestic biopharmaceutical R&D and manufacturing capabilities.
Over the last three decades accompanying Vietnam’s sustainable development, AstraZeneca has run several impactful programmes in collaboration with the Government, Ministry of Health and healthcare partners to promote disease awareness, prevention and early detection. In recent years, AstraZeneca Vietnam has received several certificates of merit from the Prime Minister and Minister of Health, for excellent contributions to Vietnam’s vaccine diplomacy, fight against COVID-19 and advancement of cancer treatment and disease awareness. The company has also been recognized among Vietnam’s Top 100 Best Places to Work (2018 – 2023) with various other industry awards from BritCham, EuroCham, and government agencies.
In Asia Area, more than 3,000 of us work amongst the most exciting growth markets, from India, SEA, Taiwan to South Korea. In these ever-evolving and complex markets, it takes entrepreneurial thinking to stay at the forefront of bringing our innovative medicines to millions of patients. Fusing our diverse minds with local ownership, we’re energized and empowered to shape a new future for AstraZeneca, our markets and our patients. We aspire to be a leader by co-developing our healthcare ecosystem with our stakeholders in Asia Area to deliver improved patient experience, outcomes and quality of life.
AstraZeneca is the fastest growing company in Oncology in Asia Area. AstraZeneca’s Oncology portfolio, which includes Haematology, will continue to power our double-digit growth aspiration in the next 3 years. We are also accelerating the expansion of our geographical footprint in rare diseases. Rare diseases is a high-growth therapy area with rapid innovation and significant unmet medical need. Over 7,000 rare diseases are known today – yet less than 1% of them have an approved treatment.
We are implementing a new Go to Market model for Haematology-Oncology & Rare Disease that establishes a Center of Excellence (Launch Hub) to lead franchise strategy and assist in-country execution across the Southeast Asian (SEA) markets